Loading
bioAffinity Technologies, Inc. Stock: price and insider trades · United States
US·Mcap US$3.7M
No insider purchase over the last 90 days. The latest was filed 05 Dec 2022.
bioAffinity Technologies, Inc.: what insiders have been doing
Every trade that managers of bioAffinity Technologies, Inc. disclose to SEC (Form 4) is tracked on this page. bioAffinity Technologies, Inc. has had no insider filing for more than a year; the last one goes back to 14 January 2025.
In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 6.2 m USD and net income of -14.9 m USD.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
62
Thresholds
n/a
Buy Volume
n/a
5 ops. · all time
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$6.15
Analyst consensus
Income statement
RevenueUS$6.1M
Gross profitUS$1.9M31% margin
EBITDA-US$14.3M-234% margin
Net income-US$14.9M-257.3% margin
Valuation
P/Book0.7x
Beta-1.12
Balance sheet & cash
Market capUS$3.7M
Total debtUS$1.2M
Free Cash Flow-US$9.4M
Debt / Equity38%
Profitability & ownership
ROE-1860.2%
ROA-125.1%
% insiders0.8%
% institutions5.6%
Last declaration on 14 January 2025
Declarations62 total
37,037 shares0Common StockSEC:0001493152-25-002150:0
21,604 shares0Common StockSEC:0001493152-25-002149:0
6,172 shares0Common StockSEC:0001493152-25-002146:0
8,641 shares0Common StockSEC:0001493152-25-002147:0
14,814 shares0Common StockSEC:0001493152-25-002148:0
100,000 shares0Common StockSEC:0001493152-24-043707:0
33,784 shares0Common StockSEC:0001493152-24-026091:0
33,784 shares0Common StockSEC:0001493152-24-026085:0
33,784 shares0Common StockSEC:0001493152-24-026089:0
33,784 shares0Common StockSEC:0001493152-24-026087:0
33,784 shares0Common StockSEC:0001493152-24-026086:0
33,784 shares0Common StockSEC:0001493152-24-026090:0
33,784 shares0Common StockSEC:0001493152-24-026092:0
33,784 shares0Common StockSEC:0001493152-24-026088:0
8,296 shares0Common StockSEC:0001493152-24-023997:0
8,296 shares0Common StockSEC:0001493152-24-024006:0
8,296 shares0Common StockSEC:0001493152-24-023993:0
8,296 shares0Common StockSEC:0001493152-24-023998:0
8,296 shares0Common StockSEC:0001493152-24-023996:0
8,296 shares0Common StockSEC:0001493152-24-023994:0
8,296 shares0Common StockSEC:0001493152-24-023995:0
8,296 shares0Common StockSEC:0001493152-24-023992:0
64,848 shares@ US$1.1636.0% of flowCommon StockSEC:0001493152-24-015789:0
64,848 shares@ US$1.16100.0% of flowCommon StockSEC:0001493152-24-015790:0
64,848 shares@ US$1.1666.2% of flowCommon StockSEC:0001493152-24-015791:0
25 of 62 declarations
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. is a company focused on developing diagnostic and treatment technologies for cancer. It aims to provide innovative solutions to improve patient outcomes.
